Global Genomics Partnering Terms and Agreements Report 2016 to 2023: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development
22 Jun 2023
DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Genomics Partnering Terms and Agreements 2016 to 2023" report has been added to
ResearchAndMarkets.com's offering.
The Global Genomics Partnering Terms and Agreements 2016 to 2023 report provides an understanding and access to the genomics partnering deals and agreements entered into by the world's leading healthcare companies.
Trends in genomics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Genomics partnering contract documents
Top genomics deals by value
The Global Genomics Partnering Terms and Agreements report provides an understanding and access to the genomics partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in genomics dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading genomics deals since 2016. Deals are listed by headline value, signed by big pharma, most active genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomics dealmaking with a brief summary followed by a comprehensive listing of genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by genomics partnering company A-Z, deal type definitions and genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in genomics partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genomics technologies and products.
Report scope
Global Genomics Partnering Terms and Agreements 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to genomics trends and structure of deals entered into by leading companies worldwide.
Global Genomics Partnering Terms and Agreements 2016 to 2023 includes:
Trends in genomics dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to over 800 genomics deal records and contract documents where available
The leading genomics deals by value since 2016
Most active genomics dealmakers since 2016
The leading genomics partnering resources
In Global Genomics Partnering Terms and Agreements 2016 to 2023, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in genomics dealmaking
2.1. Introduction
2.2. Genomics partnering over the years
2.3. Most active genomics dealmakers
2.4. Genomics partnering by deal type
2.5. Genomics partnering by therapy area
2.6. Deal terms for genomics partnering
2.6.1 Genomics partnering headline values
2.6.2 Genomics deal upfront payments
2.6.3 Genomics deal milestone payments
2.6.4 Genomics royalty rates
Chapter 3 - Leading genomics deals
3.1. Introduction
3.2. Top genomics deals by value
Chapter 4 - Most active genomics dealmakers
4.1. Introduction
4.2. Most active genomics dealmakers
4.3. Most active genomics partnering company profiles
Chapter 5 - Genomics contracts dealmaking directory
5.1. Introduction
5.2. Genomics contracts dealmaking directory
Chapter 6 - Genomics dealmaking by technology type
Companies Mentioned
1CellBiO
2bPrecise
2seventy bio
3 Sisters Surrogacy
3D Signatures
4baseCare
22nd Century
A*STAR Agency for Science
Technology and Research
A*STAR Bioinformatics Institute
A*STAR Genome Institute of Singapore
Abramson Cancer Center
Accelerated Cure Project for MS
Access to Comprehensive Genomic Profiling Coalition
ACMG Foundation for Genetic and Genomic Medicine
Active Motif
Adaptimmune
ADInstruments
Advaita
AgBiome
Agendia
AiLife Diagnostics
AKESOgen
ALS Association
Alzheimer's Drug Discovery Foundation
Amazon Web Services
America's Choice Provider Network
American Physiological Society
American Society of Clinical Oncology (ASCO)
American Type Culture Collection (ATCC)
AnimalBiome
Annoroad
APG Bio
Applied Biosystems
Argonaut
Athletigen
Auria Biobank
Avera Heart Hospital of South Dakota
Axil Scientific
Bank of America
Banner Health
Battelle
Bayer
Baylor Miraca Genetics Laboratories
BC Platforms
Becton Dickinson
Belgian Society of Medical Oncology
Berkeley Lights
BGI
Bill and Melinda Gates Foundation
BioIQ
BioMed X Innovation Center
BioTheranostics
Blackfynn
Blockchain Global
Blue Cross Blue Shield Association
For more information about this report visit https://www.researchandmarkets.com/r/oruo9x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.